Press Releases BeiGene, Ltd.

Equities

BGNE

US07725L1026

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-10 pm EDT			5-day change	1st Jan Change
161.1 ^USD	-4.45%		-0.69%	-10.66%

May. 09	Beigene Q1 Loss Shrinks as Revenue Grows; Company's Shares Nearly 7% Up	MT
May. 08	Sector Update: Health Care Stocks Lean Lower Pre-Bell Wednesday	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BeiGene Reports First Quarter 2024 Financial Results and Business Updates	May. 08	BU
BeiGene : Financial Information - Form 8-K	Apr. 26	PU
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report	Apr. 26	BU
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting	Apr. 24	BU
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	Apr. 23	BU
BeiGene Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma after Prior Chemotherapy	Mar. 15	AQ
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy	Mar. 14	BU
First Doses of BRUKINSA provided to Patients with Chronic Lymphocytic Leukemia in Low and Middle-Income Countries under Collaboration of the Max Foundation, BeiGene, and the BeiGene Foundation	Mar. 14	AQ
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation	Mar. 13	BU
BRINGING LIGHT TO THE DARKNESS OF CANCER, BEIGENE NAMED NATIONAL PARTNER OF SURVIVORSHIP AND HOPE FOR THE LEUKEMIA & LYMPHOMA SOCIETY'S LIGHT THE NIGHT	Mar. 13	AQ
BeiGene : Material Event - Form 8-K	Mar. 08	PU
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma	Mar. 07	BU
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024	Mar. 06	BU
New BeiGene Head of Europe, Global Clinical Operations appointed	Mar. 05	AQ
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia	Mar. 01	AQ
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia	Feb. 29	BU
BeiGene to Present at Upcoming Investor Conferences	Feb. 28	BU
BeiGene's Biologics License Application for TEVIMBRA for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA	Feb. 28	AQ
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA	Feb. 27	BU
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	Feb. 26	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BeiGene, Ltd.

Equities

BGNE

US07725L1026

Press Releases

Filters